- Start date
- 13 Jun 2024
- End date
- 14 Jun 2024
How to Access
The ESMO Virtual Plenaries are available to all healthcare professionals working in oncology.
No registration is required to participate. However, you will need to log in with your ESMO membership or free ESMO Account to watch the presentation(s).
Access to the ESMO Virtual Plenary will be open 15 min before each session starts.
Don't have an ESMO account?
Please set up your ESMO Account now to access the ESMO Virtual Plenary.
Programme
18:30-19:30 CEST
Welcome and introduction, Scientific background and context
Timothy Yap, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study
Xueli Bai, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China
Critical analysis and perspectives
Alberto Hernando-Calvo, Vall d'Hebron University Hospital, Barcelona, Spain
AACR Expert Commentary
Shivaani Kummar, OHSU Knight Cancer Institute, Portland, OR, USA
Discussion and Q&A (i)
Faculty and online audience
13:00-14:10 CEST
Virtual Plenary Expert Insights: Webcast of 13 June presentations, Discussion and Q&A (ii)
Faculty and online audience
Chair: Jayesh Desai, Peter MacCallum Cancer Centre, Melbourne, Australia
Xueli Bai, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China
Alberto Hernando-Calvo, Vall d'Hebron University Hospital, Barcelona, Spain
Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea
Naiyarat Prasongsook, Phramongkutklao Hospital, Bangkok, Thailand
Toshio Shimizu, Wakayama Medical University, Wakayama, Japan
